89Bio

2 stories about 89Bio
נאסדק

Teva-Linked Biotech Company 89Bio Files for Nasdaq IPO

15.10.19|CTech
Israel and San Francisco-based 89Bio raised a $60 million series A in October 2018
מייקל היידן מחקר ו פיתוח טבע

Former Teva Executives Raise $60 Million for Metabolic Disorders Venture

28.10.18|Lilach Baumer
The company’s pipeline of biologic and small molecule drug candidates was acquired from Teva